Post-ERCP Pancreatitis: Prevention, Diagnosis and Management

Medicina (Kaunas). 2022 Sep 12;58(9):1261. doi: 10.3390/medicina58091261.

Abstract

Endoscopic retrograde cholangiopancreatography (ERCP) carries a post-ERCP pancreatitis (PEP) rate of 2-10%, which could be as high as 30-50% in high-risk cases. PEP is severe in up to 5% of cases, with potential for life-threatening complications, including multi-organ failure, peripancreatic fluid collections, and death in up to 1% of cases. The risk of PEP is potentially predictable and may be modified with pharmacological measures and endoscopist technique. This review covers the definition, epidemiology and risk factors for PEP, with a focus on the latest evidence-based medical and endoscopic strategies to prevent and manage PEP.

Keywords: ERCP; non-steroidal anti-inflammatory drugs; pancreatic stenting; post-ERCP pancreatitis.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Cholangiopancreatography, Endoscopic Retrograde* / adverse effects
  • Humans
  • Pancreatitis* / diagnosis
  • Pancreatitis* / epidemiology
  • Pancreatitis* / etiology
  • Risk Factors

Substances

  • Anti-Inflammatory Agents, Non-Steroidal

Grants and funding

This research received no external funding.